Vertex Pharmaceuticals Incorporated
VRTX Healthcare Biotechnology
Vertex Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.0 billion, up 8.90% from fiscal 2024. In the quarter to June 2026, revenue grew 12.5%, EPS grew 7.96% and free cash flow grew 9.25%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years.
Follow VRTX
Vertex Pharmaceuticals Incorporated (VRTX) Gross margin
Vertex Pharmaceuticals Incorporated's gross margin over the twelve months to 30 June 2026 was 86.0%, down 0.2 percentage points from fiscal 2025 (86.2%). Over the past ten years it has ranged from 86.1% (fiscal 2024) to 89.0% (fiscal 2017); the current reading is higher than 18% of that period. That is above the Biotechnology industry median of 65.2% and above the Healthcare sector median of 53.5%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 86.2% | 0.13 |
| FY2024 | 86.1% | (1.10) |
| FY2023 | 87.2% | (0.69) |
| FY2022 | 87.9% | (0.16) |
| FY2021 | 88.1% | (0.08) |
| FY2020 | 88.1% | 1.30 |
| FY2019 | 86.8% | 0.28 |
| FY2018 | 86.6% | (2.39) |
| FY2017 | 89.0% | 1.31 |
| FY2016 | 87.6% | (0.30) |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Jun 2026 | 85.3% | (1.52) |
| Mar 2026 | 86.9% | 1.46 |
| Dec 2025 | 85.4% | (1.13) |
| Sep 2025 | 86.5% | 0.27 |
| 42 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| RPRX Royalty Pharma PLC compare | 100.0% |
| ARGX argenex SE compare | 90.2% |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 88.9% |
| VRTX Vertex Pharmaceuticals Incorporated | 86.0% |
| REGN Regeneron Pharmaceuticals, Inc. compare | 84.9% |
| ROIV Roivant Sciences Ltd. compare | 81.2% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 79.7% |
| RVMD Revolution Medicines, Inc. compare | 35.1% |
| MRNA Moderna, Inc. compare | 23.4% |
| Biotechnology industry median | 65.2% |
| Healthcare sector median | 53.5% |
| Market median | 46.2% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on VRTX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement